Search

Displaying results 5401 - 5410 of 7540 in total
  1. Drug

    Coltuximab ravtansine

    go.drugbank.com/drugs/DB06342
    Investigational

    Coltuximab ravtansine (SAR3419) targets CD19 and is being investigated for the treatment of acute lymphoblastic leukemia (ALL).

    Synonyms: Anti-CD19 humanized monoclonal antibody conjugated to DM4
  2. Drug

    Edaxeterkib

    go.drugbank.com/drugs/DB21490
    Investigational

    Edaxeterkib is under investigation in clinical trial NCT03051035 (First-in-Human Study of KO-947 in Non-Hematological Malignancies). Edaxeterkib has a monoisotopic molecular weight of 469.22 Da.

  3. Drug

    Caprospinol

    go.drugbank.com/drugs/DB05263
    Experimental

    Caprospinol (SP-233) is the first drug ever to demonstrate the correlation of clearing beta-amyloid from the brain. It also improves the brain histopathology and recovers memory function.

  4. Drug

    TAK-751S

    go.drugbank.com/drugs/DB06432
    Investigational

    TAK-751S is a synthetic analog of Shiga toxin (Stx) receptor, Gb3, produced by enterohemorrhagic _Escherichia coli_.[A260296]

  5. Drug

    Sparsomycin

    go.drugbank.com/drugs/DB04222
    Experimental

    An antitumor antibiotic produced by Streptomyces sparsogenes. It inhibits protein synthesis in 70S and 80S ribosomal systems. [PubChem]

  6. Drug

    3-Methylfentanyl

    go.drugbank.com/drugs/DB01571
    ExperimentalIllicit

    3-Methylfentanyl is an opioid analgesic and is an analog of the potent opioid, fentanyl. 3-Methylfentanyl is one of the most powerful opioid drugs sold illegally and is estimated to be between 400-6000

  7. Drug

    Nilvadipine

    go.drugbank.com/drugs/DB06712
    Approved

    Nilvadipine is a calcium channel blocker (CCB) for the treatment of hypertension.

  8. Drug

    Flunarizine

    go.drugbank.com/drugs/DB04841
    ApprovedInvestigational

    Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and periphe...

    Products: NATIL N 5MG, NATIL N 10MG
  9. Drug

    OSI-7904L

    go.drugbank.com/drugs/DB05457
    Investigational

    Current treatments also inhibit thymidylate synthase but the innovative lipid coating of OSI-7904L allows for more enduring results with administration of the TS inhibitor.

  10. Drug

    ZYCOV-D

    go.drugbank.com/drugs/DB15892
    Experimental

    The ZYCOV-D vaccine candidate was developed by Cadila Healthcare Ltd. based in India[A219758]. … The vaccine was developed using a DNA vaccine platform with a non-replicating and non-integrating plasmid carrying the gene of interest[L16503].